Home › Overweight › Oklahoma
Overweight clinical trials in Oklahoma
18 studies for Overweight are looking for participants at sites in Oklahoma.
Cities in Oklahoma
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
- Children's Physicians OU, Oklahoma City
RecruitingPhase 3
Ages 8 to 18 · All sexes · Updated Sep 30, 2026 · NCT07253285AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight
- Lynn Institute of Norman, Norman
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07720271Study to Assess the Effect and Safety of ALV-100 on Maintenance of Weight Loss
- Lynn Health Science Institute, Oklahoma City
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 28, 2026 · NCT07837973A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
- Central States Research, Tulsa
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT07794579A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
- University of Oklahoma Health Sciences Center, Oklahoma City
RecruitingPhase 3
Ages 6 to 17 · All sexes · Updated Sep 24, 2026 · NCT06672549Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
- Central States Research, Tulsa
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07353931A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes
- AURORA-2 Clinical Site, Oklahoma City
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT07743450A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
- Lynn Institute of Norman, Norman
- Lynn Health Science Institute, Oklahoma City
- Essential Medical Research, Tulsa
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07351058A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
- Delricht Research of Tulsa Clinical Trials, Tulsa
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07351045A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide
- Alliance for Multispecialty Research, LLC, Norman
RecruitingPhase 2
Ages 18 to 75 · All sexes · Updated Sep 14, 2026 · NCT06897475A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
- ACCOMPLISH-2 Research Site, Moore
- ACCOMPLISH-2 Research Site, Tulsa
- ACCOMPLISH-2 Research Site, Yukon
RecruitingPhase 3Healthy volunteers welcome
Ages 18 to 79 · All sexes · Updated Sep 11, 2026 · NCT07654374Efficacy and Safety of Ribupatide Administered Once Weekly in Participants Living With Obesity or Overweight and Diabetes
- Kailera Clinical Site, Chickasha
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07284901Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes
- Kailera Clinical Site, Chickasha
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 3, 2026 · NCT07284875Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
- Alliance for Multispecialty Research - Norman, Norman
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Sep 3, 2026 · NCT07684235Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
- Epic Medical Research - Oklahoma, Chickasha
- Lynn Health Science Institute, Oklahoma City
RecruitingPhase 3
Ages 18 to 99 · All sexes · Updated Aug 27, 2026 · NCT07575399A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus
- Research Site, Tulsa
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 25, 2026 · NCT07784725Efficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
- ACCOMPLISH-1 Research Site, Moore
RecruitingPhase 3
Ages 18 to 79 · All sexes · Updated Aug 10, 2026 · NCT07654361Intensive Glycemic Targets in Overweight and Obese Women With Gestational Diabetes
- University of Oklahoma, Norman
Recruiting
Ages 18 to 45 · Women · Updated Jun 24, 2026 · NCT05124808From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.